Date: December 8, 2022
To: All Medical Assistance Program Providers
Re: Confirmation of No Copayment for Naloxone Effective January 1, 2023, per Public Act 102-1038
___________________________________________________________________________________________________________________________________________________
This notice confirms the Department of Healthcare and Family Services (HFS) will not charge a customer copayment for Naloxone pursuant to Public Act 102-1038. This applies to customers covered under HFS' fee-for-service (FFS) program and the managed care organization (MCO) plans.
The Act states that HFS shall not impose a copayment on the coverage provided for Naloxone Hydrochloride under the Medical Assistance program. This notice verifies that pharmacies dispensing Naloxone will not charge a drug copayment for this medication under any of HFS' Medical Programs.
Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565 for FFS claims, or the applicable MCO plan.
Kelly Cunningham, Administrator
Division of Medical Programs
